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Abstract
Virus capsid assembly constitutes an attractive target for the development of antiviral therapies; a few experimental
inhibitors of this process for HIV-1 and other viruses have been identified by screening compounds or by selection from
chemical libraries. As a different, novel approach we have undertaken the rational design of peptides that could act as
competitive assembly inhibitors by mimicking capsid structural elements involved in intersubunit interfaces. Several
discrete interfaces involved in formation of the mature HIV-1 capsid through polymerization of the capsid protein CA were
targeted. We had previously designed a peptide, CAC1, that represents CA helix 9 (a major part of the dimerization
interface) and binds the CA C-terminal domain in solution. Here we have mapped the binding site of CAC1, and shown that
it substantially overlaps with the CA dimerization interface. We have also rationally modified CAC1 to increase its solubility
and CA-binding affinity, and designed four additional peptides that represent CA helical segments involved in other CA
interfaces. We found that peptides CAC1, its derivative CAC1M, and H8 (representing CA helix 8) were able to efficiently
inhibit the in vitro assembly of the mature HIV-1 capsid. Cocktails of several peptides, including CAC1 or CAC1M plus H8 or
CAI (a previously discovered inhibitor of CA polymerization), or CAC1M+H8+CAI, also abolished capsid assembly, even when
every peptide was used at lower, sub-inhibitory doses. To provide a preliminary proof that these designed capsid assembly
inhibitors could eventually serve as lead compounds for development of anti-HIV-1 agents, they were transported into
cultured cells using a cell-penetrating peptide, and tested for antiviral activity. Peptide cocktails that drastically inhibited
capsid assembly in vitro were also able to efficiently inhibit HIV-1 infection ex vivo. This study validates a novel, entirely
rational approach for the design of capsid assembly interfacial inhibitors that show antiviral activity.
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Introduction
Virus morphogenesis involves the self-assembly of the viral
capsid through specific interactions between protein subunits,
which makes this process an excellent target for antiviral research.
In recent years, a number of experimental capsid assembly
inhibitors have been identified by screening available compounds,
or by selection from chemical or peptide libraries. In addition, the
remarkable knowledge acquired on the structure of viruses and the
determinants of molecular recognition has made feasible a
complementary antiviral approach, based on the rational design
of inhibitors able to competitively interfere with interactions
between capsid subunits.
Antiviral research has been most active on the development of
effective therapies against the human immunodeficiency virus
(HIV). Current therapies against HIV involve the use of cocktails
of drugs able to inhibit the activity of the viral reverse
transcriptase, protease or integrase, or virus entry into cells.
Despite the success of this combined approach, the increasing
emergence of drug-resistant HIV variants is becoming a serious
concern, and demands the development of new anti-HIV agents to
be included in future combination therapies (reviewed in ref. [1]).
Assembly of the HIV-1 capsid is being actively studied to an
extraordinary level of detail (recently reviewed in refs. [2–5]), and
there is a growing interest in the investigation of new anti-HIV
approaches based on the inhibition of capsid assembly.
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During HIV-1 morphogenesis, the capsid protein (CA)
participates in two distinct assembly events. The first event occurs
during formation of an immature, non-infectious virus in the cell,
and involves the self-assembly of a spherical capsid comprising up
to 5000 molecules of the Gag polyprotein, of which CA constitutes
a part. The second event occurs during virus maturation. Gag is
proteolytically processed, the immature capsid disassembles, and
about 1000–1500 released CA molecules self-associate to form a
mature, conical-shaped capsid. The mature capsid is structurally
organized essentially as a lattice of CA hexamers. The CA subunits
are composed of two domains, the N-terminal domain (NTD) and
the C-terminal domain (CTD). Within each hexamer, each CA
subunit is connected with another through NTD-NTD interfaces
and NTD-CTD interfaces; each hexamer is connected to the
six neighboring hexamers through CTD-CTD dimerization
interfaces.
Capsid-like particles with the structural organization of mature
HIV-1 capsids can be efficiently assembled in vitro from free CA
molecules under non-physiological, very high ionic strength
conditions [6–8]. More recently, CA assembly was achieved in
vitro in close to physiological conditions, including low ionic
strength and a very high chemical activity (effective concentration) of
CA [9]; this was done by adding high concentrations of an inert
macromolecule to mimic the macromolecularly crowded environ-
ment inside the maturing HIV-1 virion [4,9]. The availability of
simple in vitro assembly assays, and the remarkable structural and
biochemical properties of CA, provide ample opportunities for the
development of inhibitors of HIV-1 capsid assembly.
A few inhibitors of immature or mature HIV-1 capsid assembly
have been recently discovered (reviewed in refs. [5,10–13]) by
combinatorial approaches based on random libraries of small
organic molecules (CAP-1 [14]; PF-3450074 [15,16], and the
dodecapeptide CAI [17]). CAP-1, PF-3450074 and peptide
NYAD-1 (a conformationally restricted derivative of CAI [18]),
were able to penetrate cultured cells and inhibit HIV-1 infection ex
vivo. CAP-1 and PF-3450074 bind to different sites in NTD
[15,19]. CAI and its derivative NYAD-1 bind to a hydrophobic
pocket in CTD [20–22]; CAI not only inhibits mature capsid
assembly but also facilitates capsid disassembly [23]. In addition,
a-hydroxy glycineamide interfered with HIV-1 morphogenesis
[24–26], and a dendrimeric compound bound CTD and weakly
interfered with CA polymerization in vitro [27]. Despite these and
other advances using different viral systems [28–31], no drugs
based on inhibition of capsid assembly have been yet approved for
clinical use against HIV-1 or any other virus.
As a novel approach, we have undertaken the rational design of
peptides that could act as inhibitors of HIV-1 capsid assembly by
mimicking capsid structural elements involved in intersubunit
interfaces to competitively inhibit CA oligomerization. The first
targeted interface has been the CTD-CTD dimerization interface.
Its structural description in the dimer in solution [32,33]; (Fig. 1A)
is consistent with descriptions as a part of the mature HIV-1 capsid
[34–38]. This interface is essentially formed by the parallel
packing of helix 9 (Fig. 1A), with the participation of interactions
between residues in the 310 helix of a monomer and residues in
helices 9 and 10 of the other monomer. As the isolated CTD
dimerizes with the same affinity as full-length CA [32], it likely
includes all the energetically significant CTD-CTD interactions
present in the mature capsid. This has allowed a detailed
quantitative thermodynamic dissection of this interface [39].
The structural and thermodynamic data on the CTD
dimerization interface summarized above led us to the design of
a 20-mer peptide (CAC1) that represents the sequence of helix 9,
and includes most of the energetically important residues at the
CTD dimerization interface. We showed then that CAC1 is able
to bind CTD with an affinity only 5-fold lower than the
dimerization affinity of the complete CTD [40].
In the present study we have i) rationally designed variants of
the CAC1 peptide to increase its solubility and CTD binding
affinity; ii) mapped the binding site in CTD of CAC1 and CAC1-
derived peptides; iii) designed four additional peptides that
represent other CA helical segments also involved in mature
capsid assembly; iv) tested the inhibitory activity of the designed
peptides, alone or in combination, on the in vitro assembly of the
mature HIV-1 capsid; and v) transported the peptides into HIV-1-
susceptible cells using a heterologous cell-penetrating peptide, and
analyzed the inhibitory activity of the peptides, alone or in
combination, on HIV-1 infection in cultured cells. The results
validate an entirely rational approach for the design of interfacial
inhibitors of virus capsid assembly in vitro that show antiviral
activity ex vivo.
Materials and Methods
Synthetic peptides
CAC1 (E175QASQEVKNWMTETLLVQNA194) [40], CAC1-
derived peptides CAC1C (E175SASSSVKAWMTETLLVQ-
NA194),CAC1M(SE175SAASSVKAWMTETLLVAN193TSS) and
a control, non CTD-binding, thioredoxin binding peptide
(ESLPDYGDDSDDNTLGTEEQRSIVNVSQ) derived from
pea chloroplast fructose-1,6-biphosphatase (Fbase), were synthe-
sized and purified by Genscript, NJ, USA. Peptides H2
(K30AFSPEVIPMFSALSEGAT48), H3 (Y40SALSEGATPQDL-
fNTMLNT58), H4 (H62QAAMQMLKETINEEAAEWDRVH84),
H8 (K158EPFRDYVDRFYKTLRAEQ176), CAI (ITFEDLL-
DYYGP’’ [17]), and also some batches of CAC1 and CAC1M,
were synthesized and purified by the Peptide Synthesis Facility,
Universitat Pompeu-Fabra, Barcelona, Spain. N-terminus fluores-
cein (FITC)-labelled CAI and rhodamine-labelled peptides CAI,
CAC1M and H2 were obtained from the latter source. All
peptides were amidated at the C-terminus. Numbering refers to
amino acid position in the CA protein sequence. The Chariot
peptide transfection reagent was from Active Motif.
Biological materials
NB324K cells (kindly provided by Prof. J.M. Almendral) were
used to set up the peptide transport protocol. NB324K cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco)
supplemented with 5% fetal bovine serum (FBS, Gibco), 2 mM L-
glutamine, 75 U/ml streptomycin and 75 mg/ml penicillin G, at
37uC in a 5% CO2 atmosphere. Human astroglioma cell lines
(U87-CD4-CXCR4; AIDS Research and Reference Reagent
Program, National Institutes of Health (NIH), USA; catalog
number 4036) expressing CD4 and CXCR4 receptors were used
for peptide transport and HIV-1-production-infection inhibition
assays. U87-CD4-CXCR4 cells were cultured in DMEM
supplemented with 10% FBS, 0.5 mg/ml geneticin and 1 mg/ml
puromycin, at 37uC, in a 5% CO2 atmosphere. For infection of
U87-CD4-CXCR4 cells the HXB2 strain of HIV-1 was used.
Protein expression and purification
The 15N-labelled, monomeric CTD mutant W184A was
obtained by using Bioexpress medium (Cambridge Isotope
Laboratories, MA, USA). CA protein and the isolated CTD
(either unlabelled or labelled) were purified as described previously
[39]. Protein stocks were run in SDS-PAGE gels and found to be
essentially pure. Protein concentration was determined as
described [41].
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Fluorescence spectroscopy
Spectra were collected on a Cary Eclipse spectrofluorimeter
(Varian, CA, USA). A concentration of 20 mM CTD and
increasing peptide concentrations were used for titration experi-
ments carried out at 25uC in 50 mM phosphate buffer pH 7.0.
Excitation wavelength was 280 nm or 295 nm, and emission
fluorescence was collected between 300 nm and 400 nm. The
excitation and emission slits were set to 5 nm. The response time
was 1 s. The dissociation constant of each complex was calculated
by fitting the changes observed either in: (i) the fluorescence
intensity at a particular wavelength; or (ii) the value of the average
energy ,l. [42] for a fixed CTD concentration versus the
concentration of added peptide as described [40].
Circular dichroism (CD) spectroscopy
Spectra were collected at 25uC in 50 mM phosphate buffer
pH 7.0 using a J810 spectopolarimeter (Jasco, Japan). Far-UV
measurements were performed using equimolar amounts of CTD
and the corresponding peptide (20 mM or 200 mM) in 0.1 cm-
pathlength quartz cells (Hellma). Molar ellipticities, [H], were
calculated as described [40].
(a) Steady state CD measurements. Spectra were acquired
with a response time of 2 s, and averaged over 6 scans, with a scan
speed of 50 nm/min. The step resolution was 0.2 nm, and the
band-width was 1 nm. Experiments aimed at analysing the self-
association of the peptides and estimation of the dissociation
constant were carried out as described previously [40].
(b) Thermal-denaturation CD analysis. The ellipticity at
222 nm was followed using a rate of 60uC/h, and a response time
of 8 s. The [protein]/[peptide] concentrations used were 20/
20 mM, 20/40 mM, 20/60 mM or 200/200 mM. Fitting of the
sigmoidal curves was carried out by using the program
Kaleidagraph (Abelbeck Software).
Isothermal titration calorimetry (ITC)
ITC measurements were performed by using a VP-ITC
isothermal titration calorimeter (MicroCal, MA, USA). Measure-
ments were carried out at 25uC in 12 mM Tris or phosphate
buffer pH 7.0. The sample cell (1.4 ml) was loaded with CTD at
20 mM; the corresponding peptide was loaded into the syringe at a
concentration of 400 mM. Twenty-eight injections of 10 ml were
added sequentially to the sample cell every 400 s to ensure that the
reaction was completed (as detected by the calorimetric signal
reaching the baseline level before the next injection). The amount
of power required to maintain the reaction cell at constant
temperature after each injection was monitored as a function of
time. The isotherms (differential heat upon binding versus the
molar ratio: [peptide]/[CTD]) were fitted to a single-site model
assuming a 1:1 stoichiometry for the CTD:peptide complex. Data
were analyzed with software package Origin 7.0 (OriginLab)
provided by the instrument supplier. As a control experiment, the
individual dilution heats for the isolated peptides were determined
under the same experimental conditions described above, by
carrying out identical injections of the peptide into the sample cell,
which contained only buffer.
Figure 1. Structure of CTD, and determination of the binding affinity for CTD of CAC1-derived peptides. (A) Ribbon model of the three
dimensional structure of the CTD dimer [32]. The two monomers are represented in green or blue. Helix 9 is labelled. (B) Sequence of CAC1 including
helix 9 residues, and of designed CAC1-derived peptides. (C) Variation in ,l. of the fluorescence emission spectrum of wild-type dimeric CTD with
the concentration of added CAC1C. Fitting to a 1:1 binding isotherm as described [40] is indicated by a thin line. A similar affinity constant was
obtained when the fluorescence intensity at 315 nm instead of ,l. was represented. (D) Variation in fluorescence emission intensity at 315 nm of
wild-type dimeric CTD with the concentration of added CAC1M.
doi:10.1371/journal.pone.0023877.g001
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NMR spectroscopy
NMR spectra were acquired at 20uC on a Bruker Avance
DRX-500 spectrometer (Bruker GmbH, Germany) equipped with
a triple resonance probe and z-pulse field gradients. Sodium
trimethylsilyl [2,2,3,3-2H4] propionate (Sigma) was used as the
internal chemical shift reference in the homonuclear experiments.
All experiments were carried out in 50 mM phosphate buffer
pH 7.0. Assignments of the heteronuclear single quantum
coherence (HSQC) NMR spectra were those previously obtained
for the monomeric CTD [43,44].
(a) 2D 15N-1H-HSQC-NMR spectra. All spectra were
acquired in the phase-sensitive mode. Frequency discrimination
in the indirect dimensions was achieved by using the States-TPPI
method [45]. The 2D-15N-HSQC experiments [46] were acquired
with 4 K data points in the 1H dimension and 200 scans were
acquired in the 15N axis. The spectral width was 15 ppm in the 1H
dimension and 35 ppm in the indirect 15N one. Water was
suppressed with the WATERGATE sequence [47]. The
concentration of CTD W184A was in all cases 120 mM, and the
corresponding peptide concentration was four-fold higher. To
identify CTD residues potentially involved in peptide binding,
changes in normalized peak intensity were taken into account, as
significant changes in chemical shifts are not observed when
different compounds are specifically bound to this protein [27],
and for other protein-ligand complexes (e.g. ref. [48]). Changes in
intensity were small but entirely reproducible and were
quantitated by determining the intensity of the signals in the
HSQC spectra and normalizing them with respect to the signal of
Leu231 (the CTD C-terminal residue); in that way, errors in
protein concentration and/or in the comparison between two
spectra acquired at different days with two samples were avoided.
Only those residues whose normalized intensities in the absence
and in the presence of CAC1C or CAC1M showed differences
above a threshold of 10 units (Table S1) were considered to be
affected by binding. As an example, the row corresponding to
Arg154 in CTDW184A, in the absence or presence of CAC1C, is
shown in Fig. S1. We also acquired an HSQC spectrum in the
presence of the Fbase peptide with CTDW184A at a 2:1
peptide:protein molar ratio.
(b) Measurement of T2 (transverse relaxation time). We
measured T2 of the mutant peptides, and as a control that of
CAC1, by using the 1-1 echo sequence (at the echo-times of
2.9 ms and 400 ms) [49]. Then, since the correlation time, tc, is
tc<1/T2 [50], the molecular mass M of the biomolecule, about
twice the tc, can be estimated. We measured the intensity and the
width of Gly156 (the most down-field shifted signal). Given the
errors inherent to the technique [50], and the M of the peptides,
we estimated that variations larger than 10% in the measured T2
are significant. Peptide concentrations were in the range of 50 mM
or 200–300 mM for CAC1 or CAC1A/CAC1M, respectively.
(c) Translational diffusion measurements (DOSY
experiments). Translational self-diffusion measurements were
performed with the pulsed-gradient spin-echo sequence to
determine the aggregation state of the peptides. Measurements
were carried out as described [51]. The duration of the gradient
was 3 ms, and the time between both gradients was 150 ms. The
most up-field shifted methyl groups of the peptides (those between
0.5 and 1 ppm) were used to calculate intensities. Peptide
concentrations were in the range of 50 mM or 200–300 mM for
CAC1 or CAC1A/CAC1M, respectively.
To determine the D of each peptide and, from this value, its
corresponding hydrodynamic radius (Rh), we used a previously
developed approach [52]. The Rh of dioxan was 2.12 A˚, and its
experimentally determined D, under our conditions, was
8.1761026 cm2 s21. The gradient strength was calibrated by
using the D for the residual proton water line in a sample
containing 100% D2O in a 5 mm tube, as described [51].
Kinetic analysis of CA polymerization in vitro
Assembly reactions were carried out as described previously
[9,53] with some modifications. In general, the polymerization
mixtures contained 50 mM sodium phosphate buffer pH 7.4,
2.25 M NaCl, 20 mM CA, and 100 g/l Ficoll-70 (GE HealthCare)
as a macromolecular crowding agent. Where indicated, Ficoll-70
was omitted and the final CA concentration was raised to 46 mM.
The experiments were initiated by introducing an appropriate
volume of a CA solution in 50 mM phosphate buffer into a
spectrophotometer cuvette (10-mm pathlength, 20 mm2 internal
section), and the assembly reaction was triggered by adding the
appropriate volume of a solution containing 4 M NaCl, 179 g/l
Ficoll-70 in 50 mM sodium phosphate buffer pH 7.4, to get the
final concentrations desired for each component in a final volume
of 500 ml, followed by rapid mixing by repeated inversion of the
cell. The pH of the final reaction mixture was checked in a test
sample. For inhibition assays, CA was mixed with the appropriate
amounts of the peptides, and incubated for 30 minutes before
triggering the reaction as indicated above. The time-dependent
increase in the optical density at 350 nm as a measure of the light
scattered by the assembled particles was monitored at 25uC using
a UV-1603 spectrophotometer (Shimadzu, Japan), with data
points collected every six seconds. Traces of the variation in the
turbidity were analyzed as described previously [9,53].
Transport of peptides into cells and fluorescence
microscopy
To transport the peptides into NB324K or U87-CD4-CXCR4
cells a commercial cell-penetrating peptide (Chariot, Active Motif)
was used, according to the manufacturer’s recommendations. For
fluorescence microscopy analyses, Chariot-peptide binding was
accomplished by incubating a mixture containing between 5 mg
and 50 mg of either FITC-labelled peptide or rhodamine-labelled
peptide and the Chariot peptide at a 1:1 molar ratio in 100 ml
aliquots. Each 100 ml aliquot of the preincubated mixture was
added to one well of a 24-well plate containing NB324K or U87-
CD4-CXCR4 seeded the previous day (5?104 and 1.5?105 cells/
well, respectively) and 100 ml of serum-free DMEM medium were
added. The cells were incubated for 1–3 h, 800 ml DMEM
containing 10% FBS were added, and incubation was continued
for 1 h. Cells were fixed with a 1:1 methanol:acetone solution,
their nucleus were stained with 49,6-diamidino-2-phenylindol
dihydrochloride (DAPI, Calbiochem), and cells were examined
and imaged using an Axiovert200 (Zeiss) fluorescence microscope
and/or a LSM-510 (Zeiss) confocal fluorescence microscope.
Flow cytometry analysis
FITC-labelled peptides were transported into NB324K or U87-
CD4-CXCR4 cells as described above. Then, the cells were
washed three times with phosphate-buffered saline (PBS) and
incubated 15 minutes at 37uC with 0.25% (w/v) trypsin to remove
the FITC-peptide that could remain attached to the cell
membrane. Trypsin was inactivated by adding DMEM/10%
FBS, and the cells were pelleted and resuspended in PBS / 1%
bovine serum albumin (BSA) / 1% FBS. Propidium iodide (Sigma-
Aldrich) was added to a final concentration of 1 mg/ml to label
dead cells. The resuspended cells were analyzed in a FACSCalibur
flow cytometer (Becton Dickinson, USA).
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Cytotoxicity assays
The peptides were evaluated for toxicity when transported into
cells by using a modified tetrazolium-based colorimetric method
(MTT assay) [54]. Briefly, cells treated with the peptides were
incubated for 72 h, treated with a solution of 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich)
at 7.5 mg/ml, and incubated for 2 h at 37uC. Then, an acidified
isopropanol solution was added, and the absorbance at 550 nm
and 620 nm was determined.
Peptide inhibition of HIV-1 production and infection in
cultured cells
U87-CD4-CXCR4 cells from cultured monolayers were
collected using 0.25% trypsin and resuspended in DMEM
supplemented with 10% FBS (without antibiotics). Cells were
seeded in 96-well plates at a density of 3.56104 cells/well and
incubated for 24 h. Then, the cells were incubated as described
above with mixtures of the corresponding peptides and the
Chariot peptide at the appropriate concentrations. After three
hours of incubation, the cells were washed with PBS and infected
with HIV-1 at a multiplicity of infection of 0.0015 (0.0015
TCID50/cell). After incubation for 2 h at 37uC, the cells were
washed with PBS and DMEM supplemented with 10% FBS,
0.5 mg/ml geneticin and 1 mg/ml puromycin were added, and the
infected cells were further incubated at 37uC. Viral replication was
quantified by measuring HIV-1 CA (p24 antigen) production in
the culture supernatant 72 h after infection, using an enzyme-
linked immunoassay (INNOTEST HIV-antigen, Innogenetics).
Analyses of structural models
Personal computers, a Silicon Graphics workstation and the
programs RasMol [55], Pymol [56] and Whatif [57] were used.
Results
Design of CAC1-derived peptides and analyses of their
solubility and CTD-binding affinity
Peptide CAC1 represents the sequence of helix 9 in CA (Figs. 1A
and 1B) and proved able to bind CTD, but it also showed a
tendency to aggregate [40]. We found that CAC1 includes a
region (CA residues 176 to 184) with a high propensity for amyloid
fibril formation, according to the ZipperDB database [58]; this
prediction is in qualitative agreement with that of the AMYPbd
database [59]. We hypothesized that breaking amyloid-like
signatures by carefully chosen amino acid substitutions could
decrease the tendency of CAC1 to aggregate. However, the
substituted peptide should preserve the helix 9 residues we had
found to be energetically critical for CTD-CTD dimerization [39].
This line of reasoning led to the design of a first CAC1-derived
peptide, CAC1C (Fig. 1B) in which Q176, Q179 and E180 were
replaced by serine and N183 by alanine. Based on CAC1C, a
second variant peptide, CAC1M (Fig. 1B) was designed by: i)
replacing S178 by alanine to improve helix propensity, and also
because this substitution in CTD led to an increase in dimerization
affinity; ii) replacing Q192 by alanine to further increase binding
affinity, as this substitution in CTD increased dimerization affinity
by over one order of magnitude [39]; and iii) adding further serine
residues at both termini (and replacing A194 by threonine) to
increase solubility, and to compensate for loss of hydrophilicity
caused by some of the other substitutions.
We first analyzed whether the CAC1-derived peptides CAC1C
and CAC1M had any tendency to self-associate. For both
peptides, CD measurements showed a variation in molar ellipticity
at 222 nm with increasing peptide concentrations (Fig. S2); in
addition, NMR experiments showed that the diffusion coefficient
and the molecular mass calculated from the relaxation measure-
ments were higher than expected for a monomeric species
(Table 1). The hydrodynamic radius (Rh) of the three peptides
was similar (Table 1). The apparent dissociation constant for the
self-association process determined by steady-state CD was
comparable for CAC1C, CAC1M and the unmodified CAC1
peptide (Table 1). Together, the above results indicate that both
peptides, like its parent CAC1, still had a tendency to aggregate.
However, both variant peptides did show an increased solubility
compared to CAC1. In the conditions used for NMR experiments,
which involved long incubations at a relatively high temperature,
CAC1 concentrations higher than 50 mM led to precipitation [40],
while CAC1C and CAC1M remained fully soluble even at
200 mM.
We used next several biophysical techniques to analyze whether
CAC1C and CAC1M are able to bind CTD. Thermal
denaturation of CTD followed by CD in the absence or presence
of different amounts of either peptide was used first. Binding of the
peptide to the native state of CTD, in the absence of binding to the
denatured state, is expected to lead to an increase in the melting
temperature (Tm) of the protein [60,61]. Analysis of the data
obtained by far-UV CD showed that the shape and/or the Tm of
CTD changed upon addition of CAC1C or CAC1M (Fig. S3).
Furthermore, irreversibility was observed in the presence of the
peptides. These results provided evidence of an interaction
between the peptides and CTD, and suggest that the peptides
may interact not only with the folded state but also, to a certain
extent, with the unfolded state of CTD.
We then attempted to measure the binding affinity of CAC1C
and CAC1M for CTD by using ITC. This technique yielded a
single binding isotherm with CAC1 [40]; however, it did not yield
Table 1. Parameters for self-association and CTD binding of CAC1-derived peptidesa.
Peptide Mr
b (kDa) Self-association KD (mM) Rh
c (A˚)
T2-relaxation time
(ms) and (Mr
d) (kDa) CTD-binding KD (mM)
CAC1 2.319 963e 7.7 53 (7.5) 50630e
CAC1C 2.152 3.160.5 6.9 40 (9.8) 1968
CAC1M 2.499 3.260.6 8.9 80 (5.3) 861
aAll measurements were carried out at 25uC, except for the determination of the Rh, which was at 20uC.
bMolecular mass for the peptide monomer calculated from its amino acid sequence.
cHydrodynamic radius of the peptide.
dMolecular mass for the peptide calculated from the relaxation measurements.
eData taken from [40], and shown here for completeness.
doi:10.1371/journal.pone.0023877.t001
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a clear result with the CAC1-derived peptides (Fig. S4) although
these peptides did interact with CTD, as demonstrated by using
several other techniques (see below). One possibility to explain the
ITC results is that the CTD-peptide interaction could involve a
small global apparent enthalpy; in addition, the absence of a
significant buffer ionization enthalpy effect on the interaction may
indicate that there is no net proton exchange with the bulk solution
upon CTD-peptide complex formation.
As an alternative to ITC, we used spectrofluorimetry to
determine the binding affinity for CTD of the CAC1-derived
peptides (Figs. 1C and 1D). For the two peptides, CTD
fluorescence decreased upon addition of increasing concentrations
of either peptide, suggesting interactions with either the sole
tryptophan of the protein (W184, centrally located at the
dimerization interface), or with its neighborhood. Fitting of the
variation in fluorescence intensity or ,l. yielded an apparent
equilibrium dissociation constant Kd that, for CAC1C and
especially CAC1M, was smaller than the Kd determined for
CAC1 using the same approach [40] (Table 1). Thus, the rational
modification of CAC1 led to peptides that showed a higher
solubility, and a moderately increased affinity for CTD.
Mapping the binding site in CTD of CAC1 and CAC1-
derived peptides
To locate the binding sites of CAC1 and CAC1-derived
peptides on the CTD structure we carried out 2D 15N-1H-HSQC
spectroscopic measurements of the monomeric CTD mutant
W184A in the absence or presence of the peptides. The
monomeric mutant closely mimics the conformation of a
monomeric intermediate during (non-mutated) CTD dimerization
[43,62]. We used monomeric CTD instead of dimeric CTD to
facilitate i) the assignment of resonances by precluding severe
signal broadening arising from the dimerization equilibrium
[22,43,63], and ii) comparison with the results of previous analyses
that used the same approach to map the binding site in CTD of
the CAI peptide and its derivative NYAD-1 [16,17,22].
The results obtained (Table S1 and Fig. 2) were consistent with
what was expected from peptides that mimicked helix 9: most
CTD residues whose signals in the HSQC spectra showed the
largest variations on peptide binding were at or close to the CTD
dimerization interface and overlapped substantially with the
position for helix 9 in the CTD dimer (compare Figs. 2B and
2C). Also as expected, the binding sites of CAC1 and related
peptides overlapped extensively (Figs. 2A and 2C). In particular,
residues 184, 185, 188, located at the central part of CA helix 9,
and residues 150, 154, 190, 200 and 203 are at, or close to, the
binding sites of all three peptides and the CTD dimerization
interface. In the presence of shorter mutant CAC1 peptides, CTD
yielded HSQC spectra in which the residues whose signal
intensities changed were different from those observed in the
presence of CAC1, CAC1C and CAC1M. This indicated that the
shortened mutant peptides bind at a different CTD region than
CAC1, consistent with the lack of inhibitory activity on CA
polymerization of the shortened peptides (R.D., R.B., M.G.M. and
J.L.N., unpublished results). As expected, in the presence of a
Fbase peptide, that was unable to bind CTD, no variation in signal
intensity for any CTD residue was observed. These results
provided an additional control to the specificity and approximate
definition of the binding sites identified in CTD for CAC1,
CAC1C and CAC1M. The HSQC mapping results are also
Figure 2. Mapping by NMR spectroscopy of the binding site in CTD of CAC1 and CAC1-derived peptides. (A) Mapping on the CTD
sequence of the residues affected by peptide binding. Red, green or blue circles denote residues affected by binding of CAC1, CAC1C or CAC1M,
respectively. (B, C) Surface model of one of the monomeric subunits in the CTD dimer. In (B) the residues involved in the CTD dimerization interface
are coloured magenta. The ribbon tracing of the helix 9 main chain is superimposed. In (C) the residues affected by binding of the peptides are
colored as follows: bright red, residues affected by binding of any peptide; dark red, orange or brown, residues affected by binding of CAC1 and
CAC1C, CAC1 and CAC1M, or CAC1C and CAC1M, respectively.
doi:10.1371/journal.pone.0023877.g002
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entirely consistent with the inhibition of CTD dimerization by
CAC1 [40] and with the activity and specificity of CAC1 and
derived peptides as inhibitors of capsid assembly (see next).
Inhibition of the in vitro assembly of HIV-1 capsid-like
particles by CAC1 and CAC1-derived interfacial peptides
The putative inhibitory activity of peptide CAC1 on HIV-1
capsid assembly had not been previously tested. To analyze this
possibility, we have used an in vitro assay that allows CA
polymerization into capsid-like particles [6–8]. In order to increase
the chemical activity of CA using low protein concentrations, a
macromolecular crowding agent (Ficoll-70) was added to the CA
polymerization mixtures [9,53]. We have repeatedly confirmed by
electron microscopy that the increase in turbidity observed on CA
polymerization corresponds to the formation of tubular structures
with the basic structural organization of authentic mature HIV-1
capsid-like structures ([9] and Fig. S5), as previously determined by
different authors using the same procedure in various conditions
[6–8,34].
The isolated CTD was used here as a positive control for
efficient inhibition of HIV-1 capsid assembly in vitro (Fig. 3A). A
peptide unable to bind CA did not show any inhibitory activity,
even at a very high peptide:CA molar ratio (Fig. 3B). In contrast,
CAC1 was able to inhibit capsid assembly with an efficiency that
approached that of the complete CTD (Fig. 3B). This observation
is in full agreement with the results described above on binding
affinity for CTD and the extensive overlapping between the CAC1
binding site and the CTD dimerization interface. CAC1C was
able to inhibit capsid assembly with an efficiency that was not
significantly higher than that of CAC1. However, CAC1M did
reproducibly show a moderately increased inhibitory activity
compared to CAC1 (about 20% higher reduction in total capsid
production, 30% higher reduction in polymerization rate at a
peptide:CA molar ratio of 5) (Fig. 3C); this result is consistent with
the somewhat increased binding affinity for CTD of the CAC1M
variant peptide compared to CAC1 (Table 1).
By excluding the crowding agent, the CA polymerization rate
and the amount of capsid formed were drastically reduced, as
expected from theoretical considerations on macromolecular
crowding and our previous experimental work [9,53]. However,
by substantially increasing CA concentration, efficient assembly
was restored. Testing in these conditions the inhibitory activity of
peptides CAC1, CAC1M and other peptides led to results (Fig. S6)
that were qualitatively similar to those obtained in the presence of
a crowding agent.
Design of other interfacial peptides that mimic the
sequence of different helical regions of CA involved in
mature HIV-1 capsid assembly, and in vitro analysis of
their inhibitory activity on capsid assembly
The results described above showed that the rationally designed
CAC1 peptide and, especially, its improved variant CAC1M
closely approach in vitro the inhibitory activity of the complete
CTD domain on HIV-1 capsid assembly. Thus, we decided to
attempt the design of further inhibitors of HIV-1 capsid assembly
by targetting additional CA oligomerization interfaces, using an
approach similar to that followed for CAC1 [40].
CA helices 2 and 3 in NTD are critically involved in the NTD-
NTD interfaces and CA hexamerization; CA helices 4 in NTD
and 8 in CTD are critically involved in NTD-CTD heterodimer-
ization within each CA hexamer [64] (Figs. 4A and 4B). Thus,
synthetic peptides that represent the sequences of those four helical
segments were designed (peptides H2, H3, H4 and H8
respectively; Fig. 4B), and tested in vitro for activity as potential
interfacial inhibitors of mature HIV-1capsid assembly, either in
the presence (Fig. 4C) or absence of a macromolecular crowding
agent.
Peptides H2, H3 and H4 were not able to inhibit the in vitro
assembly of HIV-1 capsid-like particles, even at the highest
peptide:CA molar ratios tested. In contrast, peptide H8 did
substantially and reproducibly inhibit capsid assembly, although its
inhibitory activity was lower than that of CAC1 and CAC1M
(Fig. 4C).
Inhibition of the in vitro assembly of the HIV-1 capsid by
cocktails of CA-binding peptides
Peptides CAI and its conformationally restricted derivative
NYAD-1 had been previously shown to be efficient in vitro
inhibitors of mature HIV-1 capsid assembly [17]. CAI was also
very efficient at inhibiting in vitro capsid assembly under
macromolecular crowding conditions (Fig. 5A), although its
Figure 3. In vitro inhibition of HIV-1 capsid assembly by CAC1 and CAC1-derived peptides. Reaction kinetics of CA polymerization was
followed by measurement of the optical density at 350 nm as a function of time after triggering the reaction. (A) Inhibition by free full-length CTD,
used as a reference inhibitor. (B) Inhibition by CAC1. (C) Inhibition by CAC1M. The CA concentration was 20 mM, and 100 g/l of Ficoll-70 as an inert
crowding agent was used. The traces are colored as follows: no free CTD or peptides added (black); an inactive peptide added at a peptide:CA molar
ratio of 10, added as a negative control (grey); added CTD (A), CAC1 (B) or CAC1M (C) at inhibitor:CA molar ratios of 1 (blue), 2 (green), 5 (pink) or 10
(red).
doi:10.1371/journal.pone.0023877.g003
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inhibitory activity was reduced in these conditions [53]. As the
binding sites in CA of CAI/NYAD-1, CAC1/CAC1C/CAC1M,
and H8 are different, we considered the use of cocktails of some of
these interfacial peptides to inhibit HIV-1 capsid assembly at least
as efficiently as with single peptides, but using lower doses of each
peptide. In a putative in vivo application, such an approach could
reduce secondary effects of individual peptides as well as the
probability of virus escape.
CAI and NYAD-1 have essentially the same sequence and bind
to the same site in CTD with a similar affinity, so we considered
one of them would be enough for inclusion in our experiments as a
reference and analysis of combined effects. We chose CAI because,
unlike NYAD-1 and like the other peptides in our study, CAI is
readily prepared, non-conformationally restricted and intrinsically
unable to penetrate cells. Among the CAC1 peptides we chose
CAC1M because of its higher solubility and affinity for CTD
(Table 1). Cocktails of sub-inhibitory doses of peptides CAC1M,
H8 and/or CAI were used in CA polymerization assays (Fig. 5).
Although the individual peptides can achieve efficient assembly
inhibition at higher doses (see above), at the low concentrations
chosen for the new set of assays they caused only a minor
inhibitory effect on capsid assembly. In these conditions, a mixture
of peptides CAI+H8 was no better inhibitor than either peptide
alone (Fig. 5B). In contrast, a mixture of peptides CAC1M+H8 led
to an additive inhibitory effect (Fig. 5C). Remarkably, capsid
assembly was essentially abolished when mixtures of peptides
CAC1M+CAI (Fig. 5D), or CAC1M+H8+CAI (Fig. 5E) at those
same low concentrations of each peptide were used. The three-
peptide cocktail prevented the formation of even the slightest
traces of assembled particles. The results revealed a functional
exclusion between H8 and CAI, an additive effect between
CAC1M and H8, and even a synergy between CAI and CAC1M,
regarding the inhibitory activity of these peptides on the in vitro
assembly of the mature HIV-1 capsid.
Inhibition of HIV-1 infectivity by interfacial peptides
The structural study described here has shown that the designed
peptides, alone or in combination, can efficiently inhibit the in vitro
assembly of viral particles with the organization of authentic
mature HIV-1 capsid, validating the successful design of interfacial
inhibitors of capsid assembly. A full characterization of the
inhibitory activity of these peptides in the more complex
environment of infected cells will of course require an additional
investigation using different, virological techniques. However, as a
final part of our present study, and as a preliminary experiment for
future ex vivo studies, we have tested whether the designed peptides
could act as experimental antiviral agents by inhibiting HIV-1
infection of susceptible cultured cells. In order to do so, the
peptides were first transported into cells.
Transport of peptides into cells susceptible to HIV-1
infection, and analysis of cytotoxicity. Use of a cell-
penetrating heterologous peptide had allowed transport of CAI
into cells [65], and we employed the commercial Chariot peptide
to follow a similar approach. The conditions were defined using
mainly HIV-1-susceptible U87-CD4-CXCR4 cells. Due to the
high autofluorescence in these cells observed in the green channel,
rhodamine-labelled peptides were used. To confirm that peptides
with very different sequences could be transported, peptides
CAC1M, CAI and H2 were tested in these assays. The
fluorescence results (Figs. 6A, 6B and 6C, and results not shown)
provided the first evidence that Chariot-mediated transport of
peptides into HIV-1-susceptible cells had been achieved.
Additional evidence for transport of peptides into U87-CD4-
CXCR4 cells was provided by using FITC-labelled CAI in flow
cytometry assays (Fig. 6D). Finally, we used confocal fluorescence
microscopy to confirm that the peptides were not merely bound to
cells, but actually internalized (Fig. 6E).
Inhibition of HIV-1 infectivity by peptides. We have
tested the antiviral action of CAC1, CAC1M and H8. CAI
(contrary to its conformationally restricted derivative NYAD-1)
had previously failed to inhibit HIV-1 infection ex vivo as this
peptide is unable to penetrate cells [17]. Thus, as we had done in
the polymerization assays (see above), we included in the infectivity
assays CAI in addition to the designed peptides. Also, CAI was
somewhat more efficient than CAC1 and CAC1M and
substantially more efficient than H8 at inhibiting in vitro mature
Figure 4. Inhibition of in vitro capsid assembly by peptides H2, H3, H4 and H8. (A) Crystallographic structural model of the CA hexamer [64].
Each CA monomer is shown in a different color. (B) Closeup of the arrangement of two neighboring CA monomers (labelled 1 and 2) in the CA
hexamer depicted in panel (A). The orientation has been modified to show the CTD-NTD and NTD-NTD interfaces more clearly. Helices 2 in blue, 3 in
red, 4 in orange and 8 in yellow are highlighted, and labelled H2, H3, H4 and H8, respectively. The sequences of the corresponding peptides are
indicated. (C) Reaction kinetics of CA polymerization using the conditions described in the legend for Fig. 3. The traces are colored as follows: no
peptide added (black); peptide H2 (blue); peptide H3 (red); peptide H4 (brown), all at a peptide:inhibitor molar ratio of 10; peptide H8 at a peptide:CA
ratio of 5 (yellow); peptide H8 at a peptide:CA molar ratio of 10 (orange).
doi:10.1371/journal.pone.0023877.g004
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capsid assembly, and this provided a reference for comparison of
their inhibition of HIV-1 infection.
The inhibitory activity of the peptides on HIV-1 infection was
tested using cultured U87-CD4-CXCR4 cells. The concentrations
of peptides used were not toxic to the cells. Cells were incubated
with a mixture of the peptides (alone or in combination) and the
Chariot peptide, and subsequently infected with HIV-1 strain
HXB2 at a multiplicity of infection of 0.0015. The amount of
progeny virus produced at 72 h post-infection was determined by
titrating the amount of CA (p24 antigen) produced. Representative
results are shown in Fig. 7. In the absence of added peptides, the
infected cells produced considerable amounts of virus (yielding on
average 37,000 pg/ml of p24 antigen). As expected, a negative
control peptide (H4) that was unable to inhibit HIV-1 capsid
assembly in vitro, was also unable to inhibit HIV-1 production ex
vivo, even at peptide concentrations close to 2 mM.
Peptides CAC1, CAC1M, H8 and CAI alone, that did
efficiently inhibit HIV-1 capsid assembly in vitro, showed at most
a weak inhibitory activity on HIV-1 production ex vivo that
required high (.1 mM) concentrations (Fig. 7). As these same
purified peptides were very active at inhibiting CA polymerization,
their poor individual effect on the inhibition of HIV-1 infection
does not seem to be related mainly to a weak potency, or to a
minor component of the peptide preparation being the only active
species. Rather, Chariot-mediated transport of these peptides was
an inefficient process and, in addition, short peptides are easily
degraded inside cells. Thus, the poor inhibitory activity of HIV-1
infection by these peptides could be due to their very low
concentration inside the infected cells.
Most remarkably, in spite of their inefficient transport and any
degradation inside the cell, mixtures of CAC1/CAC1M+H8;
CAC1/CAC1M+CAI; and CAC1/CAC1M+H8+CAI, substan-
tially inhibited HIV-1 production (by about 90%) at the doses
tested (Fig. 7), acting as antiviral agents ex vivo. These results are
consistent with the high inhibitory activity of these mixtures on
capsid assembly in vitro.
Figure 5. Inhibition of in vitro capsid assembly by cocktails of interfacial peptides. Reaction kinetics of CA polymerization using the
conditions described in the legend for Fig. 3. (A) Inhibition by CAI under the macromolecular crowding conditions used for testing the inhibitory
activity of the designed peptides described in this work. The traces are colored as follows: no peptide added (black); an inactive peptide at a
peptide:CA molar ratio of 10 (grey); CAI added at peptide:CA ratios of 0.1 (light blue), 0.2 (blue), 0.3 (green), 0.4 (orange) or 0.5 (pink). (B) Inhibition by
a cocktail of CAI and H8. No peptide added (black); an inactive peptide at a peptide:CA ratio of 10 (grey); CAI added alone at a peptide:molar ratio of
0.2 (blue); H8 added alone at a peptide:CA molar ratio of 5 (orange); a cocktail of CAI and H8 added at the same molar ratios used for each peptide
alone (pink). (C) Inhibition by a cocktail of CAC1M and H8. No peptide added (black); an inactive peptide at a peptide:CA ratio of 10 (grey); H8 added
alone at a peptide:molar ratio of 5 (orange); CAC1M added alone at a peptide:CA molar ratio of 2 (green); a cocktail of H8 and CAC1M added at the
same molar ratios used for each peptide alone (pink). (D) Inhibition by a cocktail of CAC1M and CAI. No peptide added (black); an inactive peptide at
a peptide:CA ratio of 10 (grey); CAI added alone at a peptide:molar ratio of 0.2 (blue); CAC1M added alone at a peptide:CA molar ratio of 2 (green); a
cocktail of CAI and CAC1M added at the same molar ratios used for each peptide alone (pink). (E) Inhibition by a cocktail of three peptides: CAC1M,
CAI and H8. No peptide added (black); an inactive peptide at a peptide:CA molar ratio of 10 (grey); CAI added alone at a peptide:molar ratio of 0.2
(blue); CAC1M added alone at a peptide:CA molar ratio of 2 (green); H8 added alone at a peptide:molar ratio of 5 (orange); a cocktail of CAI, CAC1M
and H8 added at the same molar ratios used for each peptide alone (pink).
doi:10.1371/journal.pone.0023877.g005
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Discussion
Peptide CAC1 as an efficient assembly inhibitor
It may seem surprising that unconstrained, unstructured
peptides like CAC1 and derivatives, that represent only a part of
the CTD dimerization interface, are able to bind CTD and inhibit
assembly of mature HIV-1 capsid-like particles almost as efficiently
as the full-length, folded CTD itself. Part of the explanation may
be related to the unusual features of the CTD-CTD interface. This
interface resembles a typical high-affinity interface in buried
surface area, number of residues, presence of a hydrophobic core
[32,33], and in containing as many as 9 residues per monomer
that individually contribute as much as $6 kcal/mol to the
dimerization reaction [39]. However, contrary to other structur-
ally similar oligomerization interfaces [66], the CTD-CTD
interface has a remarkably low affinity. Steric constraints imposed
by the geometry of the capsid lattice [38] may contribute to capsid
instability by distorting the minimum free energy, unconstrained
conformation of the dimerization interface as present in the
isolated CTD dimer. However, even when unconstrained in
solution, CTD dimerization is a low-affinity reaction (Kd about
10 mM) [32]. This intrinsically low affinity can be traced to i) the
presence of interfacial residues that are involved in coulombic
repulsions and other unfavorable interactions between CTD
monomers [39,67]; and ii) the very low thermodynamic stability
of the monomeric form of CTD [62], which may underlie its
unusually high structural plasticity in solution (e.g. [43,44,68]), on
ligand binding (e.g. [16,20,69]), and during immature and mature
capsid assembly (reviewed in refs. [3,4]; see also ref. [70]).
Specifically, in the CTD monomer helix 9 appears to be only
partially and/or transiently folded [43,44], and this helix must be
structured during dimerization. Thus, the success of the helix 9-
mimic CAC1 peptide and derivatives as interfacial inhibitors of
HIV-1 capsid assembly may be mainly due to the fact that a
similarly high entropic penalty must be paid for CTD-CAC1
association than for CTD-CTD association: neither the CAC1
peptide nor helix 9 in CTD are fully structured before
dimerization occurs [43].
Figure 6. Transport of assembly inhibitor peptides into cells followed by fluorescence microscopy and flow cytometry. (A, B, C)
Representative fluorescence microscopy images of U87-CD4-CXCR4 cells incubated for 3 h at 37uC with with no peptide added (A), or with 10 mg of
Rhodamine-labelled CAI (B) or CAC1M (C) in complex with Chariot at a 1:1 molar ratio. The cell nuclei are stained blue using DAPI; the presence of
rhodamine-peptide conjugates is indicated by red fluorescence emission. (D) Flow cytometry analysis of U87-CD4-CXCR4 incubated for 3 h at 37uC
with no peptide added (stained with propidium iodide) (red line), 50 mg of FITC-labelled CAI in the absence (green line) or in complex with Chariot at
a 1:1 molar ratio (blue line). (E) Representative fluorescence confocal microscopy images of peptide-transfected cells. NB324K cells were incubated for
3 h at 37uC with 10 mg of FITC-labelled CAI in complex with Chariot (Chariot:peptide ratio of 1:1). Left, difference interference contrast image showing
the equatorial plane of several cells; center, green fluorescence emission of the same field and focal plane shown at left; right, superimposition of the
two previous images, showing the presence of FITC-peptide conjugate inside the cells.
doi:10.1371/journal.pone.0023877.g006
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Even if those entropic effects are taken into account, it is still a
fact that CAC1 includes most but not all of the CTD residues
energetically important for CTD dimerization [39]. Thus, if
bound CAC1 faithfully mimicked the conformation of helix 9 as
part of CTD, a difference in true binding affinity larger than the
one experimentally obtained could be expected (see the Results
section). In fact, our mapping of the binding site in CTD of CAC1
revealed a substantial overlap with the CTD dimerization epitope,
but the match between the two regions is far from perfect
(compare Figs. 2B and 2C). In addition, other residues generally
located close, but not at the CTD dimerization interface, were also
affected by CAC1 binding. The very similar binding sites
delineated for CAC1 and its derivatives CAC1C and CAC1M,
and their potent inhibitory activity, further supports the validity of
our mapping results.
A detailed interpretation of the observed structural and
energetic differences and similarities between the CTD dimeriza-
tion interface and the CTD-CAC1 interface must await the
elucidation of the three-dimensional structure of the CTD-CAC1
complex. In the meantime, we tentatively propose that CAC1,
despite containing the complete helix 9 sequence, may adopt on
binding to CTD a folded conformation that resembles, but not
fully mimics, that of helix 9 in dimeric CTD, while providing
enough additional contacts for preserving a relatively strong
binding to CTD. Despite the differences in binding and
conformation, the overlap would be enough for the CTD-bound
peptide to sterically impair CTD dimerization and CA polymer-
ization.
CAC1-derived peptides
Our rational design to increase CAC1 solubility and/or CTD
binding affinity led in two steps to CAC1M, a CAC1-derived
peptide that includes multiple amino acid substitutions and short
N- and C-terminal extensions. These modifications were intended
to disrupt a predicted aggregation-prone sequence, increase
solubility, increase helical propensity and/or eliminate side chains
that, in the complete CTD domain, restricted dimerization
affinity. The design was moderately successful. In particular,
substitutions S178A and/or Q192A may have contributed to some
increase in the binding affinity and inhibitory potency of the
peptide as intended. However, the affinity increase was smaller
than when the same substitutions were introduced in the full-
length CTD [39]. Again, this difference could be explained by the
fact that, on binding CTD, CAC1 does not fully reproduce the
conformation of helix 9 in the CTD domain.
Peptide H8
A novel CA-derived peptide, H8, that was designed following a
rationale similar to the one followed for CAC1 (the mimicking of
interfacial helices), was also able to inhibit capsid assembly and HIV-1
infection, which tends to validate this approach for the design of
inhibitor peptides. By comparison with the CAC1 results, it may be
reasonable to propose that H8, which represents the sequence of helix
8 in CTD at the CTD-NTD interface, may bind NTD and
competitively inhibit CTD-NTD heterodimerization during assem-
bly of the mature capsid. Peptide H8 is not as active as CAC1 as an
inhibitor of capsid assembly, probably because helix 8 (unlike helix 9),
is fully formed in the CTD monomer, while peptide H8 in solution
(like CAC1 and most short linear peptides) is not structured. Thus,
H8-CA affinity may be lower than CTD-NTD affinity partly because
of the high entropic cost of structuring this peptide.
Cocktails of peptide inhibitors
The rationally designed peptides CAC1, its improved derivative
CAC1M, and H8 add to the combinatorially selected peptide CAI
[17] and its improved derivative NYAD-1 [18] as peptide inhibitors
of HIV-1 capsid assembly in vitro and HIV-1 infectivity ex vivo. CAC1/
CAC1M and H8 expand the choices of potential lead compounds for
the design of peptidomimetics or other small molecule inhibitors of
HIV-1 assembly. In addition, the unprecedented availability of
several different peptide interfacial inhibitors allowed us to analyze
the inhibitory activity of cocktails of these inhibitors on the in vitro
assembly of the mature HIV-1 capsid.
The experiments revealed a negative interference between H8
and CAI, an additive effect between CAC1M and H8, and a
synergistic effect between CAI and CAC1M. A tentative structural
explanation for these observations can be proposed based on the
different binding sites of these peptides on the CA molecule. CAI
binds CTD at a region that involves parts of CA helices 8 and 9
[20,21]. This region is close to the CTD-CTD interface, and
clearly overlaps with the CTD-NTD interface. Thus, CAI binding
may sterically prevent CTD-NTD heterodimerization, and it may
also allosterically alter the CTD dimerization interface, without
preventing dimer formation in solution but impairing the native
quaternary organization of CA in the capsid lattice [17,20,21]. In
full-length CA, binding of CAI to CTD and of H8 to NTD could
sterically interfere with CTD-NTD association during capsid
assembly, thus explaining the negative interference of these two
peptides. In contrast, CAI and CAC1/CAC1M bind to non-
Figure 7. Ex vivo inhibition of HIV-1 infection by assembly
inhibitor peptides. Peptides H4 (as a negative control), CAC1,
CAC1M, H8, CAI and the indicated peptide cocktails were incubated
with Chariot and transported into cells, and the cells were infected with
HIV-1 strain HXB2 (0.0015 TCID50/cell) as described in Methods. The
concentrations of peptides used in the experiments shown were: H4,
0.8 mM (labelled H4l) and 1.7 mM (labelled H4h); CAC1, CAC1M, CAI
(alone or as part of a cocktail), 170 mM; H8 (alone or as part of a
cocktail), 2.6 mM. Supernatants were collected at 72 h after infection,
and the amount of CA produced (p24 antigen) was determined as
described in Materials and Methods. The values obtained were
normalized to the amount of p24 obtained in the absence of any
peptide added. 100% virus production corresponds to 37,000 pg/ml of
p24 antigen. The average and standard error from equivalent data
obtained in several experiments are indicated.
doi:10.1371/journal.pone.0023877.g007
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overlapping patches in CTD, which would explain the observed
additivity when mixtures of these peptides were used. The
conformational rearrangement induced in CTD by the binding
of CAI could even potentiate the binding of CAC1/CAC1M
(and/or viceversa), leading to the observed synergistic inhibitory
effects of these two peptides on capsid assembly. In analogy with
current combination therapies, this observation provides initial
support on the possibility of using cocktails of interfacial assembly
inhibitors instead of a single assembly inhibitor, however potent, to
reduce the emergence of resistant virus variants, which would need
to accumulate mutations at different oligomerization interfaces.
Inhibition of virus infection ex vivo
The present study has contemplated the rational design or
modification, structural analysis and evaluation of peptides as
inhibitors of HIV-1 capsid assembly using biophysical techniques.
However, to provide an initial proof on their antiviral activity, we
carried out some experiments regarding their assisted transport
into cultured cells, and their inhibitory action on HIV-1 infection.
Similarly to that observed in in vitro assembly experiments, a
mixture of peptides H8 and CAI was no better inhibitor of HIV-1
infection than each peptide alone, while a mixture of CAC1/
CAC1M plus either H8 or CAI showed a substantial inhibition of
virus infection. This observation provides a first suggestion that the
antiviral activity of these peptides ex vivo is related, as expected
from the in vitro results, with inhibition of mature HIV-1 capsid
assembly. It could be argued that unless the peptides are
incorporated in high enough concentrations within the budding
virion, inhibition of mature capsid assembly inside the detached,
maturing virus particle would not take place. However, it may be
worth noting at this stage that the CTD-CTD and NTD-CTD
interfaces observed in the mature capsid may not participate in
immature capsid assembly [3,4]. Thus, Gag molecules forming the
immature capsid could bind substantial quantities of CAC1,
CAC1M and H8 peptides to their sterically unimpeded binding
sites in CA, thus locally increasing peptide concentration inside the
budding virion.
It must be emphasized, however, that the present study has
focused on the conceptual and experimental framework that goes
from the structure-based design and modification of assembly-
inhibition peptides to their structural characterization and
evaluation in a defined, controlled, previously validated in vitro
system that provides a simplified model of mature HIV-1 capsid
assembly. It is not intended as a virological study in the complete
mechanism of action of these peptides in the more complex
environment inside HIV-1 infected cells, which will require a full
set of different approaches and techniques.
To conclude, we have shown that rationally designed and
improved peptides CAC1, CAC1M and H8 mimicking the
sequence of protein helices involved in assembly of the mature
HIV-1 capsid can act as efficient interfacial inhibitors of capsid
assembly in vitro and have antiviral activity ex vivo.
Supporting Information
Figure S1 A representative row of the 15N-1H HSQC
spectra of CTDW184A in the absence (black) or in the
presence (blue) of CAC1M. In the presence of peptide, the signal
for Arg154 shows a decrease in intensity while the signal for Tyr164
and Phe168 remain unchanged. Data were acquired at 25uC.
(TIF)
Figure S2 Analysis of self-association of peptides
CAC1C (A) and CAC1M (B) by far-UV CD. Traces indicate
the fitting to 1:1 stoichiometry. The ellipticity data were obtained
at 222 nm (A) or 230 nm (B) and normalized. Data were acquired
at 25uC.
(TIF)
Figure S3 Thermal denaturation of CTD in the absence
or presence of CAC1-derived peptides followed by far-
UV CD. Traces correspond to wild-type CTD in the absence of
any peptide (black lines) or equimolar amounts of peptide (blue
lines) CAC1C (A) or CAC1M (B). For convenience, the scales in
(A) and (B) are different. The Tms obtained in the absence of
peptides or in the presence of CAC1C were respectively
327.860.6 K and 325.062.0 K. The Tm in the presence of
CAC1M could not be accurately determined, but the different
shape of the transition relative to absence of the peptide provided
evidence of interaction.
(TIF)
Figure S4 ITC analysis of CAC1 (A) or CAC1M (B)
binding to wild-type CTD. In each case, the titration curve is
shown on top and the binding curve at the bottom. Experiments
were carried out at 25uC.
(TIF)
Figure S5 Transmission electron microscopy of CA
assemblies obtained in polymerization assays. Two
magnifications are shown in (A) and (B). The tubular CA polymers
observed present the same basic structural organization of
authentic mature HIV-1 capsid-like structures with no pentameric
‘‘defects’’ [34].
(TIF)
Figure S6 In vitro inhibition of HIV-1 capsid assembly
by CAC1 (A), CAC1C (B) or CAC1M (C) in the absence of
molecular crowding. Reaction kinetics of CA polymerization
was followed as indicated in Fig. 3. CA concentration was 20 mM
and no crowding agent was added. The traces are colored as
follows: no free peptides added (black); an inactive peptide at a
peptide:CA molar ratio of 10 (grey); CAC1 (A), CAC1C (B) or
CAC1M (C) peptides added at inhibitor:CA molar ratios of 0.2
(blue) or 0.5 (orange).
(TIF)
Table S1 Residues of CTDW184A whose signal intensity in the
HSQC spectra changed upon peptide addition.
(DOC)
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